Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Ischemic Retinopathies: Advanced Delivery Methods and Cutting Edge Therapies
share announcement

Ischemic Retinopathies: Advanced Delivery Methods and Cutting Edge Therapies

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (25 July 2022) | Viewed by 5269

Special Issue Editors

Dr. Yohei Tomita

E-Mail Website
Guest Editor
Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Interests: retinal diseases and metabolism; angiogenesis; vitreoretinal surgery; pathologic myopia
Special Issues, Collections and Topics in MDPI journals
Dr. Deokho Lee

E-Mail Website
Guest Editor
Laboratory of Photobiology, Keio University School of Medicine, Tokyo 160-8582, Japan
Interests: neuroprotection; ocular ischemia; hypoxia; retinal ganglion cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Retinal ischemia is one of the major causes of visual impairment and blindness and is associated with various eye diseases such as diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity. The numbers of patients with diseases related to retinal ischemia continue to increase year after year. Even though research scientists have been trying to develop promising therapeutics or advanced methods for the delivery of current treatments in retinal ischemia, more investigation is still needed. Additionally, the precise pathophysiologic mechanisms of the associations between various eye diseases and retinal ischemia are not yet fully understood.

The scope of this Special Issue is to summarize and enlarge advanced methods for the delivery of diverse ischemic retinopathies and suggest cutting-edge therapies in retinal ischemia. Original research papers and reviews are welcomed.

Dr. Yohei Tomita
Dr. Deokho Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetic retinopathy
  • retinopathy of prematurity
  • retinal vein occlusion
  • retinal artery occlusion
  • ocular ischemic syndrome
  • age-related macular degeneration
  • pathologic myopia
  • glaucoma
  • retinal tumors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 5882 KiB  
Article
Integrated Analysis of Metabolomics and Lipidomics in Plasma of T2DM Patients with Diabetic Retinopathy
by Chun Ding, Nan Wang, Zicong Wang, Wenyun Yue, Bingyan Li, Jun Zeng, Shigeo Yoshida, Yan Yang and Yedi Zhou
Pharmaceutics 2022, 14(12), 2751; https://doi.org/10.3390/pharmaceutics14122751 - 08 Dec 2022
Cited by 10 | Viewed by 1718
Abstract
Diabetic retinopathy (DR) is a major cause of blindness worldwide and may be non-proliferative (NPDR) or proliferative (PDR). To investigate the metabolomic and lipidomic characteristics of plasma in DR patients, plasma samples were collected from patients with type 2 diabetes mellitus (DR group) [...] Read more.
Diabetic retinopathy (DR) is a major cause of blindness worldwide and may be non-proliferative (NPDR) or proliferative (PDR). To investigate the metabolomic and lipidomic characteristics of plasma in DR patients, plasma samples were collected from patients with type 2 diabetes mellitus (DR group) with PDR (n = 27), NPDR (n = 18), or no retinopathy (controls, n = 21). Levels of 54 and 41 metabolites were significantly altered in the plasma of DR patients under positive and negative ion modes, respectively. By subgroup analysis, 74 and 29 significantly changed plasma metabolites were detected in PDR patients compared with NPDR patients under positive and negative ion modes, respectively. KEGG analysis indicated that pathways such as biosynthesis of amino acids and neuroactive ligand-receptor interaction were among the most enriched pathways in altered metabolites in the DR group and PDR subgroup. Moreover, a total of 26 and 41 lipids were significantly changed in the DR group and the PDR subgroup, respectively. The panel using the 29-item index could discriminate effectively between diabetic patients with and without retinopathy, and the panel of 22 items showed effective discrimination between PDR and NPDR. These results provide a basis for further research into the therapeutic targets associated with these metabolite and lipid alterations. Full article
(This article belongs to the Special Issue Ischemic Retinopathies: Advanced Delivery Methods and Cutting Edge Therapies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 3761 KiB  
Review
Selective Activation of the Wnt-Signaling Pathway as a Novel Therapy for the Treatment of Diabetic Retinopathy and Other Retinal Vascular Diseases
by Huy Nguyen, Sung-Jin Lee and Yang Li
Pharmaceutics 2022, 14(11), 2476; https://doi.org/10.3390/pharmaceutics14112476 - 16 Nov 2022
Cited by 3 | Viewed by 2827
Abstract
Retinal ischemia, often associated with various disorders such as diabetic retinopathy (DR), retinal vein occlusion, glaucoma, optic neuropathies, stroke, and other retinopathies, is a major cause of visual impairment and blindness worldwide. As proper blood supply to the retina is critical to maintain [...] Read more.
Retinal ischemia, often associated with various disorders such as diabetic retinopathy (DR), retinal vein occlusion, glaucoma, optic neuropathies, stroke, and other retinopathies, is a major cause of visual impairment and blindness worldwide. As proper blood supply to the retina is critical to maintain its high metabolic demand, any impediment to blood flow can lead to a decrease in oxygen supply, resulting in retinal ischemia. In the pathogenesis of DR, including diabetic macular edema (DME), elevated blood glucose leads to blood-retina barrier (BRB) disruptions, vascular leakage, and capillary occlusion and dropouts, causing insufficient delivery of oxygen to the retina, and ultimately resulting in visual impairment. Other potential causes of DR include neuronal dysfunction in the absence of vascular defect, genetic, and environmental factors. The exact disease progression remains unclear and varies from patient to patient. Vascular leakage leading to edema clearly links to visual impairment and remains an important target for therapy. Despite recent advances in the treatment of DME and DR with anti-VEGFs, effective therapies with new mechanisms of action to address current treatment limitations regarding vessel regeneration and reperfusion of ischemic retinal areas are still needed. The Wnt signaling pathway plays a critical role in proper vascular development and maintenance in the retina, and thus provides a novel therapeutic approach for the treatment of diabetic and other retinopathies. In this review, we summarize the potential of this pathway to address treatment gaps with current therapies, its promise as a novel and potentially disease modifying therapy for patients with DR and opportunities in other retinal vascular diseases. Full article
(This article belongs to the Special Issue Ischemic Retinopathies: Advanced Delivery Methods and Cutting Edge Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop